Is a barrier really necessary to prevent radiculitis when using recombinant human bone morphogenetic protein-2 in proximity of nerve roots?
Smoljanovic
Tomislav
T
Cimic
Mislav
M
Bojanic
Ivan
I
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D016025:Bone Transplantation; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage*; D015552:Injections, Intralesional; D015337:Multicenter Studies as Topic; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D011843:Radiculopathy / Q000209:etiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013123:Spinal Fusion / Q000009:adverse effects* / Q000295:instrumentation; D013126:Spinal Nerve Roots / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate